Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors

2014 ◽  
Vol 61 (10) ◽  
pp. 1792-1797 ◽  
Author(s):  
Robin E. Norris ◽  
Suzanne Shusterman ◽  
Lia Gore ◽  
Jodi A. Muscal ◽  
Margaret E. Macy ◽  
...  
Keyword(s):  
Young Adults ◽  
Polyethylene Glycol ◽  
Solid Tumors ◽  
Phase 1 ◽  
Adolescents And Young Adults

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 10536-10536 ◽  
Author(s):  
Ami Vijay Desai ◽  
Garrett M. Brodeur ◽  
Jennifer Foster ◽  
Stacey L. Berg ◽  
Ellen M. Basu ◽  
...  
Keyword(s):  
Young Adults ◽  
Solid Tumors ◽  
Phase 1 ◽  
Adolescents And Young Adults ◽  
Phase 1 Study ◽  
Alk Inhibitor

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e21519-e21519
Author(s):  
Emily Gustava Greengard ◽  
Robin Lesley Williams ◽  
Xiaowei Liu ◽  
Olga Militano ◽  
Terrence Lee Fisher ◽  
...  
Keyword(s):  
Young Adults ◽  
Solid Tumors ◽  
Kidney Injury ◽  
Sleeping Beauty ◽  
Adolescents And Young Adults ◽  
Recommended Dose ◽  
Receptor Interaction ◽  
Dose Selection ◽  
Stage Design ◽  
Grade 3

e21519 Background: Semaphorins regulate tumor progression, immune responses, and angiogenesis. SEMA4D was identified as a candidate proto-oncogene by a Sleeping Beauty forward genetic screen that induced osteosarcoma in mice. SEMA4D is expressed on tumors, including osteosarcoma, and in the tumor microenvironment. VX15/2503, a humanized IgG4 monoclonal antibody, binds SEMA4D, blocks receptor interaction and enhances the anti-tumor immune response in preclinical studies. This trial aimed to determine the tolerability and recommended dose of VX15/2503 in patients with relapsed/refractory solid tumors and activity in patients with osteosarcoma. Methods: Part A enrolled patients age≤ 21y with refractory solid tumors to assess the tolerability of VX15/2503 (20 mg/kg) IV every 14 days x 2 doses/cycle. The recommended dose was one that was tolerated and achieved sustained target saturation. Up to 6 additional children were enrolled to assess pharmacokinetics (PK). In part B, a two-stage design was used to assess the activity of VX15/2503 in patients with measurable, relapsed /refractory osteosarcoma. In part B1 patients > 21-30y accrued concurrently with part A; Part B2 (patients £ 21y) was initiated after the pediatric recommended dose was determined. Correlative studies including target saturation by VX15/2503 were required. Results: 18 eligible patients enrolled, 16 evaluable for toxicity. In part A (n = 12) the median (range) age was 12.5 (1-20) y. Diagnoses included osteosarcoma (8), neuroblastoma (2), other (2). No dose limiting toxicities (DLTs) were observed. In Part B1, (n = 6) median (range) age was 22.5 (22-30) y; one patient had cycle 1 DLTs (grade 3 acute kidney injury, creatinine increase, arthralgia and myalgia); a second patient had a later cycle DLT (grade 4 pericardial effusion). Given only 1/18 had a cycle 1 DLT, this did not impact dose selection. T-cell saturation by VX15/2503 was adequate and sustained in all patients. Conclusions: VX15/2503 was well tolerated at 20 mg/kg IV every 2 weeks and is the recommended dose in children, adolescents and young adults. The activity in osteosarcoma is under evaluation. Future trials combining VX15/2503 with novel agents are in development. Clinical trial information: NCT03320330.

A phase II study of pazopanib in children, adolescents, and young adults with refractory solid tumors.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. TPS10081-TPS10081 ◽  
Author(s):  
Alice Lee ◽  
Julia Glade Bender ◽  
Brenda Weigel ◽  
Elizabeth Fox ◽  
Anne C. Huff ◽  
...  
Keyword(s):  
Young Adults ◽  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adolescents And Young Adults

scholarly journals Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

Oncotarget ◽  
2016 ◽  
Vol 8 (14) ◽  
pp. 23851-23861 ◽  
Author(s):  
Kieuhoa T. Vo ◽  
Erin E. Karski ◽  
Nicole M. Nasholm ◽  
Shelly Allen ◽  
Fabienne Hollinger ◽  
...  
Keyword(s):  
Young Adults ◽  
Solid Tumors ◽  
Phase 1 ◽  
Oral Cyclophosphamide ◽  
Phase 1 Study ◽  
Children And Young Adults

Patterns of intensity of end-of-life care for adolescents and young adults with cancer: A population-based study.

2016 ◽  
Vol 34 (26_suppl) ◽  
pp. 132-132 ◽  
Author(s):  
Emily E. Johnston ◽  
Elysia Marie Alvarez ◽  
Olga Saynina ◽  
Lee Sanders ◽  
Smita Bhatia ◽  
...  
Keyword(s):  
Young Adults ◽  
End Of Life ◽  
Solid Tumors ◽  
Health Planning ◽  
Hematologic Malignancies ◽  
Population Based ◽  
Adolescents And Young Adults ◽  
Secondary Neoplasms ◽  
Factors Associated ◽  
Eol Care

132 Background: Cancer is the leading cause of non-accidental death amongst adolescents and young adults (AYA), aged 15-39, in the U.S. It is critical to understand end of life (EOL) care of AYA cancer decedents, including use of medically intense interventions like intubation. Although desired by some, most patients prefer a natural death. We sought to determine rates of medically intense interventions at end of life for AYA cancer decedents and associated factors. Methods: Using the California Office of Statewide Health Planning and Development private administrative database linked to death certificates, we performed a retrospective population based analysis of patients aged 15-39 with cancer who died between 2000-2010. We used previously defined administrative codes indicative of intense EOL care: intubation, CPR, hospital re-admission, and ICU admission in the last 30 days of life, and location of death. The frequencies of each intense item were calculated and multivariate logistic regression was used to determine clinical (including treatment at specialty center vs non) and socio-demographic factors associated with each item and receipt of ≥ 2 items. Results: The 8,978 AYA cancer decedents were 46% non-Hispanic white, 29% Hispanic, 10% non-Hispanic black, 11% Asian; 21% had hematologic malignancies, 70% had solid tumors, and 9% had secondary neoplasms; 58% were hospitalized only at non-specialty centers in the last 6 months of life. 62% received ≥ 1 medically intense EOL care intervention, and 32% received > 2. Factors associated with > 2 intense EOL care interventions were: non-Hispanic black (OR 1.38, 95% CI 1.16-1.65), Hispanics (1.19, 1.06-1.35), Asians (1.30, 1.10-1.52); those sometimes (2.19, 1.87-2.56) or never (1.44, 1.26-1.65) seen at specialty centers; hematologic malignancies (1.77, 1.57-2.00 ref grp: solid tumors) whereas secondary malignancies were not associated with > 2 intense markers (0.68, 0.56-0.83). Conclusions: Nearly two-thirds of the AYA cancer decedents received medically intense EOL interventions and disparities exist in receipt of such care. Further research needs to determine if the disparities are due to healthcare system, patient preference, or other factors.

scholarly journals Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Sara Akhavanfard ◽  
Roshan Padmanabhan ◽  
Lamis Yehia ◽  
Feixiong Cheng ◽  
Charis Eng
Keyword(s):  
Young Adults ◽  
Solid Tumors ◽  
Adolescents And Young Adults
Sign in / Sign up

Export Citation Format

Share Document